Paolo A. Ascierto
@pascierto
Ricercatore Oncologo presso Istituto Nazionale Tumori Fondazione Pascale di Napoli.
Medical oncologist from National Cancer Institute of Naples, Italy
ID: 523724994
13-03-2012 22:03:43
1,1K Tweet
1,1K Followers
252 Following

New #JITC article: Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020 bit.ly/43lQM8O Paolo A. Ascierto


FyI: ESMO - Eur. Oncology Cutaneous #Melanoma Living Guideline for all stages a living guideline at your fingertips ! Paolo A. Ascierto John Haanen The Angeles Clinic esmo.org/living-guideliโฆ
The mRNA cancer vaccine works, and we aim to make it available within two years. A future where this therapy becomes a reality is closer than ever. Read my interview with Secolo d'Italia here: secoloditalia.it/2025/03/loncolโฆ #CancerResearch #Oncology #Innovation
๐ ๐๐ฌ๐ญ๐ข๐ฏ๐๐ฅ ๐๐๐ฅ๐ฅ๐ ๐๐ซ๐๐ฏ๐๐ง๐ณ๐ข๐จ๐ง๐ was a great opportunity to promote a culture of health! An integrated approach to prevention means protecting our future. Thanks to #LILT & all speakers for the insightful discussion! #PreventionFirst #HealthMatters

Art and science united against melanoma. With Roberto Vecchioni, weโre turning music into a message of prevention. See you in Naples, April 15 ๐ญ ๐ napolitoday.it/benessere/saluโฆ #Melanoma #Health #Prevention
๐ค "Itโs a beautiful thing, and Iโm truly happy to do it." Prof. Roberto Vecchioni brings his "Tra il silenzio e il tuono Tour" to Naples โ a special date dedicated to cancer prevention. ๐ Teatro Augusteo | ๐๏ธ April 15, 2025 #Health #Prevention #FondazioneMelanoma
Last night in Naples: a sold-out Teatro Augusteo for Roberto Vecchioniโs concert dedicated to cancer prevention. An unforgettable evening of music, memory, and meaning. Thank you, Maestro. ๐ #MelanomaAwareness #TraIlSilenzioEIlTuono #FondazioneMelanoma crcnews.it/roberto-vecchiโฆ


#ASCO25 | Un insight di Paolo A. Ascierto sullo studio C-POST: cemiplimab in adiuvante nel paziente con #CSCC ad alto rischio. Non perdere il commento completo tra poco sul Day2 di OncoInfo! ๐ Istituto Nazionale Tumori Pascale